The 4A classification for patients with tricuspid regurgitation

Rev Esp Cardiol (Engl Ed). 2023 Nov;76(11):845-851. doi: 10.1016/j.rec.2023.02.008. Epub 2023 Mar 9.
[Article in English, Spanish]

Abstract

Introduction and objectives: Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. Clinical evaluation of TR patients is challenging. Our aim was to establish a new clinical classification specific for patients with TR, the 4A classification, and evaluate its prognostic performance.

Methods: We included patients with isolated TR that was at least severe and without previous episodes of heart failure (HF) who were assessed in the heart valve clinic. We registered signs and symptoms of asthenia, ankle swelling, abdominal pain or distention and/or anorexia and followed up the patients every 6 months. The 4A classification ranged from A0 (no A) to A3 (3 or 4 As present). We defined a combined endpoint consisting of hospital admission due to right HF or cardiovascular mortality.

Results: We included 135 patients with significant TR between 2016 and 2021 (69% females, mean age 78±7 years). During a median follow-up of 26 [IQR, 10-41] months, 39% (n=53) patients had the combined endpoint: 34% (n=46) were admitted for HF and 5% (n=7) died. At baseline, 94% of the patients were in NYHA I or II, while 24% were in classes A2 or A3. The presence of A2 or A3 conferred a high incidence of events. The change in 4A class remained an independent marker of HF and cardiovascular mortality (adjusted HR per unit of change of 4A class, 1.95 [1.37-2.77]; P<.001).

Conclusions: This study reports a novel clinical classification specifically for patients with TR that is based on signs and symptoms of right HF and has prognostic value for events.

Keywords: 4A classification; Clasificación de las 4A; Insuficiencia cardiaca derecha; Insuficiencia tricuspídea; Right heart failure; Tricuspid regurgitation.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Heart Failure* / complications
  • Heart Failure* / diagnosis
  • Humans
  • Incidence
  • Male
  • Morbidity
  • Prognosis
  • Treatment Outcome
  • Tricuspid Valve Insufficiency* / diagnosis
  • Tricuspid Valve Insufficiency* / epidemiology